GENova Biotherapeutics causes concern as media blitz culminates in stock trading suspension – update
This article was originally published in Scrip
Executive Summary
The US SEC has suspended trading in the tiny biotech newcomer GENova Biotherapeutics after its share price rose more than 30-fold. GENova burst onto the scene in September with a flurry of press releases about agreements it is signing.